Occidental in talks to sell OxyChem unit for $10 bln- FT

Occidental Petroleum is reportedly in discussions to sell its OxyChem unit for approximately $10 billion, a strategic move aimed at significantly reducing the company's substantial debt burden. This potential divestiture follows major acquisitions, including the 2019 Anadarko and 2023 CrownRock deals, and comes amidst a prolonged decline in oil prices. The sale, expected to be announced in the coming weeks, underscores OXY's ongoing efforts to deleverage and strengthen its financial position.

Analysis

Occidental Petroleum (OXY) is reportedly in late-stage negotiations to divest its OxyChem unit for approximately $10 billion. This potential transaction represents a significant acceleration of the company's long-standing deleveraging strategy and would be its largest divestiture to date. The move is a direct response to the substantial debt accrued from major acquisitions, notably the $55 billion purchase of Anadarko in 2019 and the $13 billion acquisition of CrownRock in 2023. Executing this sale is particularly critical in the current operating environment, which the article characterizes as a "prolonged decline in oil prices," pressuring the company's ability to organically reduce its debt. The reported timing of an announcement in the "coming weeks" suggests a near-term catalyst. While the sale involves shedding a major business unit, the positive ticker-specific sentiment (0.5) indicates that the market likely perceives the significant reduction in balance sheet risk as outweighing the loss of future earnings from the chemical segment.

Key Decisions for Investors

• Investors should view the potential $10 billion divestiture as a significant positive catalyst for Occidental's balance sheet, directly addressing the primary overhang of its substantial debt load.
• Monitor for an official announcement in the coming weeks, as the final sale price and terms will be critical to quantifying the precise impact on the company's leverage ratios and enterprise value.
• While the deleveraging is a clear credit positive, consider the long-term impact of losing the OxyChem business, and weigh the benefits of a strengthened balance sheet against the reduction in asset diversification and future cash flow.